Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus
Objective: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with varied morbidity and mortality. We assessed clinical presentations, autoantibody specificities and therapeutic interventions in Native American (NA) patients with SLE. Methods: Patients with SLE meeting 1997 American...
| Autores Principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artículo (Article) |
| Lenguaje: | Inglés (English) |
| Publicado: |
2018
|
| Materias: | |
| Acceso en línea: | http://repository.urosario.edu.co/handle/10336/19121 |
| id |
ir-10336-19121 |
|---|---|
| recordtype |
dspace |
| spelling |
ir-10336-191212019-09-19T12:37:54Z Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus Kheir, Joseph M Guthridge, Carla J Johnston, Jonathon R Adams, Lucas J Rasmussen, Astrid Gross, Timothy F Munroe, Melissa E Bourn, Rebecka L Sivils, Kathy L. Guthridge, Joel M. Weisman, Michael H. Wallace, Daniel J. Anaya, Juan-Manuel Rojas-Villarraga, Adriana Jarvis, James N Harley, John B. James, Judith A. Antinuclear Antibody Autoantibody Cardiolipin Antibody Double Stranded Dna Antibody Hydroxychloroquine Immunoglobulin G Antibody Immunoglobulin M Antibody Methotrexate Mycophenolate Mofetil Precipitin Adult African American American Indian Antibody Specificity Antibody Titer Article Clinical Feature Controlled Study Drug Use Enzyme Linked Immunosorbent Assay Ethnic Difference European American Female Hispanic Human Immunofluorescence Interstitial Lung Disease Major Clinical Study Male Mouth Ulcer Photosensitivity Priority Journal Race Difference Raynaud Phenomenon Sjoegren Syndrome Systemic Lupus Erythematosus Systemic Sclerosis Enfermedades Anticuerpos Lupus eritematoso Objective: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with varied morbidity and mortality. We assessed clinical presentations, autoantibody specificities and therapeutic interventions in Native American (NA) patients with SLE. Methods: Patients with SLE meeting 1997 American College of Rheumatology classification criteria (n=3148) were enrolled between 1992 and 2010 in the multiethnic, cross-sectional Lupus Family Registry and Repository. Clinical, demographic and therapeutic information were extracted from medical records using a standardised form and formalised training. Autoantibodies were assessed by indirect immunofluorescence (antinuclear antibodies (ANA) and antidouble-stranded DNA), precipitin (ENA) and ELISA (IgG and IgM anticardiolipins). Results: NA patients met SLE classification at a younger age (29.89±12.3 years) than European Americans (EA; 32.02±12.87, P=0.0157) and a similar age to African-Americans (AAs) and Hispanics (HIS). More NA patients had concurrent rheumatic diseases or symptoms, such as Raynaud's phenomenon, interstitial lung disease, Sjögren's syndrome and systemic sclerosis. Compared with EAs, NAs were more likely to have high-titre ANA (≥1:3240; P<0.0001) and had more SLE-associated autoantibodies. Autoantibodies with unknown specificities were more common in NAs (41%) compared with other racial/ethnic groups in this collection (AA: 24%, P=0.0006; EA: 17%, P<0.0001; HIS: 23%, P=0.0050). Fewer NA patients used hydroxychloroquine (68%) compared with others (AA: 74%, P=0.0308; EA: 79%, P=0.0001, HIS: 77%, P=0.0173); this was influenced by lower hydroxychloroquine use in NA patients from Latin America (32%). NA patients had higher rates of methotrexate use (28%) compared with AA (18%, P=0.0006) and HIS patients (14%, P=0.0003), higher azathioprine use (38%) compared with EA patients (30%, P=0.0105) and higher mycophenolate mofetil use (26%) compared with EA (17%, P=0.0012) and HIS patients (11%, P<0.0001). Conclusions: NA patients are diagnosed with SLE earlier in life and present worse concurrent rheumatic disease symptoms than EA patients. NA patients also are more likely to have expanded autoantibody profiles and precipitins of unknown specificities. © 2018 Article author(s). 2018 2019-02-20T20:59:09Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion 2053-8790 http://repository.urosario.edu.co/handle/10336/19121 10.1136/lupus-2017-000247 eng info:eu-repo/semantics/openAccess application/pdf Manuel, F., Ugarte-Gil, G.J.P.-E., Alarcon, G.S., Epidemiology (2016) Systemic Lupus Erythematosus |
| institution |
EdocUR - Universidad del Rosario |
| collection |
DSpace |
| language |
Inglés (English) |
| topic |
Antinuclear Antibody Autoantibody Cardiolipin Antibody Double Stranded Dna Antibody Hydroxychloroquine Immunoglobulin G Antibody Immunoglobulin M Antibody Methotrexate Mycophenolate Mofetil Precipitin Adult African American American Indian Antibody Specificity Antibody Titer Article Clinical Feature Controlled Study Drug Use Enzyme Linked Immunosorbent Assay Ethnic Difference European American Female Hispanic Human Immunofluorescence Interstitial Lung Disease Major Clinical Study Male Mouth Ulcer Photosensitivity Priority Journal Race Difference Raynaud Phenomenon Sjoegren Syndrome Systemic Lupus Erythematosus Systemic Sclerosis Enfermedades Anticuerpos Lupus eritematoso |
| spellingShingle |
Antinuclear Antibody Autoantibody Cardiolipin Antibody Double Stranded Dna Antibody Hydroxychloroquine Immunoglobulin G Antibody Immunoglobulin M Antibody Methotrexate Mycophenolate Mofetil Precipitin Adult African American American Indian Antibody Specificity Antibody Titer Article Clinical Feature Controlled Study Drug Use Enzyme Linked Immunosorbent Assay Ethnic Difference European American Female Hispanic Human Immunofluorescence Interstitial Lung Disease Major Clinical Study Male Mouth Ulcer Photosensitivity Priority Journal Race Difference Raynaud Phenomenon Sjoegren Syndrome Systemic Lupus Erythematosus Systemic Sclerosis Enfermedades Anticuerpos Lupus eritematoso Kheir, Joseph M Guthridge, Carla J Johnston, Jonathon R Adams, Lucas J Rasmussen, Astrid Gross, Timothy F Munroe, Melissa E Bourn, Rebecka L Sivils, Kathy L. Guthridge, Joel M. Weisman, Michael H. Wallace, Daniel J. Anaya, Juan-Manuel Rojas-Villarraga, Adriana Jarvis, James N Harley, John B. James, Judith A. Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus |
| description |
Objective: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with varied morbidity and mortality. We assessed clinical presentations, autoantibody specificities and therapeutic interventions in Native American (NA) patients with SLE. Methods: Patients with SLE meeting 1997 American College of Rheumatology classification criteria (n=3148) were enrolled between 1992 and 2010 in the multiethnic, cross-sectional Lupus Family Registry and Repository. Clinical, demographic and therapeutic information were extracted from medical records using a standardised form and formalised training. Autoantibodies were assessed by indirect immunofluorescence (antinuclear antibodies (ANA) and antidouble-stranded DNA), precipitin (ENA) and ELISA (IgG and IgM anticardiolipins). Results: NA patients met SLE classification at a younger age (29.89±12.3 years) than European Americans (EA; 32.02±12.87, P=0.0157) and a similar age to African-Americans (AAs) and Hispanics (HIS). More NA patients had concurrent rheumatic diseases or symptoms, such as Raynaud's phenomenon, interstitial lung disease, Sjögren's syndrome and systemic sclerosis. Compared with EAs, NAs were more likely to have high-titre ANA (≥1:3240; P<0.0001) and had more SLE-associated autoantibodies. Autoantibodies with unknown specificities were more common in NAs (41%) compared with other racial/ethnic groups in this collection (AA: 24%, P=0.0006; EA: 17%, P<0.0001; HIS: 23%, P=0.0050). Fewer NA patients used hydroxychloroquine (68%) compared with others (AA: 74%, P=0.0308; EA: 79%, P=0.0001, HIS: 77%, P=0.0173); this was influenced by lower hydroxychloroquine use in NA patients from Latin America (32%). NA patients had higher rates of methotrexate use (28%) compared with AA (18%, P=0.0006) and HIS patients (14%, P=0.0003), higher azathioprine use (38%) compared with EA patients (30%, P=0.0105) and higher mycophenolate mofetil use (26%) compared with EA (17%, P=0.0012) and HIS patients (11%, P<0.0001). Conclusions: NA patients are diagnosed with SLE earlier in life and present worse concurrent rheumatic disease symptoms than EA patients. NA patients also are more likely to have expanded autoantibody profiles and precipitins of unknown specificities. © 2018 Article author(s). |
| format |
Artículo (Article) |
| author |
Kheir, Joseph M Guthridge, Carla J Johnston, Jonathon R Adams, Lucas J Rasmussen, Astrid Gross, Timothy F Munroe, Melissa E Bourn, Rebecka L Sivils, Kathy L. Guthridge, Joel M. Weisman, Michael H. Wallace, Daniel J. Anaya, Juan-Manuel Rojas-Villarraga, Adriana Jarvis, James N Harley, John B. James, Judith A. |
| author_facet |
Kheir, Joseph M Guthridge, Carla J Johnston, Jonathon R Adams, Lucas J Rasmussen, Astrid Gross, Timothy F Munroe, Melissa E Bourn, Rebecka L Sivils, Kathy L. Guthridge, Joel M. Weisman, Michael H. Wallace, Daniel J. Anaya, Juan-Manuel Rojas-Villarraga, Adriana Jarvis, James N Harley, John B. James, Judith A. |
| author_sort |
Kheir, Joseph M |
| title |
Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus |
| title_short |
Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus |
| title_full |
Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus |
| title_fullStr |
Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus |
| title_full_unstemmed |
Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus |
| title_sort |
unique clinical characteristics, autoantibodies and medication use in native american patients with systemic lupus erythematosus |
| publishDate |
2018 |
| url |
http://repository.urosario.edu.co/handle/10336/19121 |
| _version_ |
1645141592527339520 |
| score |
12,131701 |